- Home
- TCBI vs ACAD Comparison
TCBI vs ACAD Comparison
Compare TCBI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBI
- ACAD
- Stock Information
- Founded
- TCBI 1996
- ACAD 1993
- Country
- TCBI United States
- ACAD United States
- Employees
- TCBI N/A
- ACAD N/A
- Industry
- TCBI Major Banks
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- TCBI Finance
- ACAD Health Care
- Exchange
- TCBI Nasdaq
- ACAD Nasdaq
- Market Cap
- TCBI 2.9B
- ACAD 2.5B
- IPO Year
- TCBI N/A
- ACAD 2004
- Fundamental
- Price
- TCBI $72.85
- ACAD $17.44
- Analyst Decision
- TCBI Hold
- ACAD Buy
- Analyst Count
- TCBI 15
- ACAD 15
- Target Price
- TCBI $77.00
- ACAD $24.21
- AVG Volume (30 Days)
- TCBI 546.3K
- ACAD 1.7M
- Earning Date
- TCBI 04-17-2025
- ACAD 05-07-2025
- Dividend Yield
- TCBI N/A
- ACAD N/A
- EPS Growth
- TCBI N/A
- ACAD N/A
- EPS
- TCBI 1.74
- ACAD 1.37
- Revenue
- TCBI $891,496,000.00
- ACAD $996,283,000.00
- Revenue This Year
- TCBI $44.80
- ACAD $13.07
- Revenue Next Year
- TCBI $9.26
- ACAD $10.06
- P/E Ratio
- TCBI $41.83
- ACAD $12.73
- Revenue Growth
- TCBI N/A
- ACAD 22.42
- 52 Week Low
- TCBI $56.24
- ACAD $13.40
- 52 Week High
- TCBI $91.80
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- TCBI 61.81
- ACAD 67.70
- Support Level
- TCBI $68.74
- ACAD $14.45
- Resistance Level
- TCBI $71.79
- ACAD $15.31
- Average True Range (ATR)
- TCBI 1.95
- ACAD 0.69
- MACD
- TCBI 0.91
- ACAD 0.37
- Stochastic Oscillator
- TCBI 93.77
- ACAD 94.92
About TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a secured lender, with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. The company's national lines of business provide specialized lending products to businesses throughout the United States. The bank operates in Texas' main metropolitan areas, like Austin, Dallas, Fort Worth, Houston, and San Antonio.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.